MX2018004358A - Restablecimiento de rutas biológicas para defender contra el deterioro por el envejecimiento humano y repararlo. - Google Patents
Restablecimiento de rutas biológicas para defender contra el deterioro por el envejecimiento humano y repararlo.Info
- Publication number
- MX2018004358A MX2018004358A MX2018004358A MX2018004358A MX2018004358A MX 2018004358 A MX2018004358 A MX 2018004358A MX 2018004358 A MX2018004358 A MX 2018004358A MX 2018004358 A MX2018004358 A MX 2018004358A MX 2018004358 A MX2018004358 A MX 2018004358A
- Authority
- MX
- Mexico
- Prior art keywords
- component
- nicotinic acid
- combinations
- nicotinamide
- resetting
- Prior art date
Links
- 230000032683 aging Effects 0.000 title abstract 2
- 230000008236 biological pathway Effects 0.000 title 1
- 230000006866 deterioration Effects 0.000 title 1
- 239000012190 activator Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- LDHMAVIPBRSVRG-UHFFFAOYSA-O 1-methylnicotinamide Chemical compound C[N+]1=CC=CC(C(N)=O)=C1 LDHMAVIPBRSVRG-UHFFFAOYSA-O 0.000 abstract 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 abstract 2
- PUEDDPCUCPRQNY-ZYUZMQFOSA-N D-ribosylnicotinate Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CC(C([O-])=O)=C1 PUEDDPCUCPRQNY-ZYUZMQFOSA-N 0.000 abstract 2
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 abstract 2
- 230000006851 antioxidant defense Effects 0.000 abstract 2
- SENPVEZBRZQVST-HISDBWNOSA-N deamido-NAD zwitterion Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 SENPVEZBRZQVST-HISDBWNOSA-N 0.000 abstract 2
- 229960004452 methionine Drugs 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- XVTDSQJAFPHQGF-UHFFFAOYSA-N 7h-purin-6-amine;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.NC1=NC=NC2=C1NC=N2 XVTDSQJAFPHQGF-UHFFFAOYSA-N 0.000 abstract 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 abstract 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 229960003237 betaine Drugs 0.000 abstract 1
- 229960001231 choline Drugs 0.000 abstract 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020956 nicotinamide riboside Nutrition 0.000 abstract 1
- 239000011618 nicotinamide riboside Substances 0.000 abstract 1
- 229910052979 sodium sulfide Inorganic materials 0.000 abstract 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen composiciones para atender uno o mas de los efectos del envejecimiento. Las composiciones comprenden un primer componente que comprende uno o mas activadores de sistemas de reparaciOn, tales como dinucleOtido de nicotinamida y adenina (NAD+), mononucleotido de nicotinamida (NMN), ribOsido de nicotinamida (NR), mononucleotido de adenina y acid° nicotinico (NaMN), dinucleotido de adenina y acid° nicotinico (NaAD), ribosido de acido nicotinico (NAR), 1- metilnicotinamida (MNM), monofosfato de adenosina ciclico (cAMP) y combinaciones de los mismos; un segundo componente que comprende uno mas donadores de metilos tales como S-5'-adenosil-L-metionina (SAM), metionina, betaina, colina, folato, vitamina B12 o combinaciones de los mismos; y un tercer componente que comprende activadores de defensas antioxidantes tales como H202, N2S, NaSH, Na2S y varios otros, incluyendo combinaciones de los mismos. Tambien se dan a conocer metodos de administracian de las composiciones dadas a conocer, o formulaciones separadas del activador de sistemas de reparacion, donadores de metilos y activadores de defensas antioxidantes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238338P | 2015-10-07 | 2015-10-07 | |
| PCT/US2016/055173 WO2017062311A1 (en) | 2015-10-07 | 2016-10-03 | Resetting biological pathways for defending against and repairing deterioration from human aging |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018004358A true MX2018004358A (es) | 2018-05-23 |
Family
ID=58488381
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004358A MX2018004358A (es) | 2015-10-07 | 2016-10-03 | Restablecimiento de rutas biológicas para defender contra el deterioro por el envejecimiento humano y repararlo. |
| MX2022013626A MX2022013626A (es) | 2015-10-07 | 2018-04-09 | Restablecimiento de rutas biologicas para defender contra el deterioro por el envejecimiento humano y repararlo. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013626A MX2022013626A (es) | 2015-10-07 | 2018-04-09 | Restablecimiento de rutas biologicas para defender contra el deterioro por el envejecimiento humano y repararlo. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190060336A1 (es) |
| EP (1) | EP3359259B1 (es) |
| JP (2) | JP2018530614A (es) |
| KR (1) | KR20180063179A (es) |
| CN (1) | CN108290059A (es) |
| AU (2) | AU2016335968B2 (es) |
| BR (1) | BR112018007153A2 (es) |
| CA (2) | CA3001483A1 (es) |
| HK (1) | HK1258406A1 (es) |
| IL (3) | IL299824B2 (es) |
| MX (2) | MX2018004358A (es) |
| RU (1) | RU2768936C2 (es) |
| SG (1) | SG11201802933YA (es) |
| WO (1) | WO2017062311A1 (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035664B1 (ru) | 2015-08-05 | 2020-07-23 | МЕТРО ИНТЕРНЭШНЛ БАЙОТЕК, ЭлЭлСи | Производные никотинамидмононуклеотида и их применение для лечения заболевания или расстройства, связанного с биосинтезом над+ |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| CN106470687A (zh) * | 2015-12-11 | 2017-03-01 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的保健品中的应用及其保健品 |
| CN106659729A (zh) * | 2015-12-11 | 2017-05-10 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物 |
| EP3430156A1 (en) * | 2016-03-16 | 2019-01-23 | DSM IP Assets B.V. | Microbial production of nicotinic acid riboside |
| US11389468B2 (en) * | 2017-03-17 | 2022-07-19 | Elysium Health, Inc. | Nicotinamide riboside for use in treating or preventing liver damage |
| US20180289729A1 (en) * | 2017-04-07 | 2018-10-11 | Robert John Petcavich | Combination therapy for treatment of human neurodegenerative diseases |
| WO2018200357A1 (en) * | 2017-04-26 | 2018-11-01 | Elysium Health, Inc. | Methods and compositions of improving fertility |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| CN107198232A (zh) * | 2017-06-21 | 2017-09-26 | 浏阳市红杉农业科技发展有限公司 | 一种延年益寿的保健品 |
| US11260078B2 (en) | 2017-07-25 | 2022-03-01 | Insilico Medicine Ip Limited | Method of treating senescence with multi-stage longevity therapeutics |
| US11373732B2 (en) | 2017-07-25 | 2022-06-28 | Deep Longevity Limited | Aging markers of human microbiome and microbiomic aging clock |
| WO2019032627A1 (en) * | 2017-08-09 | 2019-02-14 | Intervene Immune, Inc. | PHARMACEUTICAL PRODUCTS AND MEANS FOR REVERSE INVERSION OF HUMAN AGING |
| JP2020530460A (ja) | 2017-08-10 | 2020-10-22 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | ニコチンアミドモノヌクレオチドを使用する治療の組成物および方法 |
| WO2019054485A1 (ja) * | 2017-09-14 | 2019-03-21 | めぐみ 田中 | 老化防止剤及び老化防止方法 |
| WO2019104065A1 (en) * | 2017-11-22 | 2019-05-31 | Turrinii Pharmaceutical, Llc | Anti-aging methods and compositions |
| CN107875171A (zh) * | 2017-12-08 | 2018-04-06 | 深圳市莱利赛生物科技有限公司 | 一种脐带间充质干细胞药物在促进皮肤伤口愈合中的应用 |
| BR112020016534A2 (pt) | 2017-12-28 | 2020-12-22 | Kansas State University Research Foundation | Método para aumentar a quantidade da carne e/ou de melhorar a qualidade da carne em um animal de abate domesticado e uso de ribosídeo de nicotinamida |
| AU2019214858B2 (en) | 2018-01-30 | 2023-02-02 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| KR20200131852A (ko) * | 2018-03-13 | 2020-11-24 | 누치도 리미티드 | 조성물 |
| WO2019209840A1 (en) * | 2018-04-23 | 2019-10-31 | Elysium Health, Inc. | Methods and compositions for treating rheumatoid arthritis |
| US20210121488A1 (en) * | 2018-06-21 | 2021-04-29 | Societe Des Produits Nestle S.A. | Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor |
| EP3850954A4 (en) * | 2018-09-14 | 2022-06-08 | Megumi Tanaka | ANTI-AGING AGENT AND ANTI-AGING PROCESS |
| CN109566826A (zh) * | 2018-10-15 | 2019-04-05 | 河南省锐达医药科技有限公司 | 一种抗衰老提高免疫力美容的组合物 |
| WO2020089236A1 (en) | 2018-11-02 | 2020-05-07 | Unilever Plc | Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same |
| EP3897666A2 (en) | 2018-12-17 | 2021-10-27 | Mitopower LLC | Nicotinyl riboside compounds and their uses |
| CN109884007B (zh) * | 2019-02-18 | 2020-10-27 | 西安交通大学 | 一体化同步dna纳米器件及其活细胞多靶标成像应用和成像方法 |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| WO2020206160A1 (en) * | 2019-04-05 | 2020-10-08 | Rejuvenation Therapeutics | Compositions comprising nicotinamide adenine dinucleotide-related compounds and use thereof |
| WO2020234729A1 (en) * | 2019-05-17 | 2020-11-26 | Insilico Medicine Ip Limited | Deep proteome markers of human biological aging and methods of determining a biological aging clock |
| US20200397807A1 (en) * | 2019-06-18 | 2020-12-24 | MitoPower, LLC | Nicotinyl riboside compounds and their uses |
| CN111617094A (zh) * | 2019-12-30 | 2020-09-04 | 上海互众药业有限公司 | 一种延缓衰老的复方制剂及其制备方法 |
| BR112022013428A2 (pt) * | 2020-01-06 | 2022-09-13 | Juvn3 Holdings Llc | Composições e métodos para aumentar a vitalidade e a longevidade celular e diminuir o envelhecimento molecular |
| WO2021198399A1 (en) * | 2020-04-01 | 2021-10-07 | Société des Produits Nestlé S.A. | Compositions and methods containing n-acetylcystein and nicotinamide riboside for prevention and treatment of neurological diseases and conditions |
| WO2021202245A1 (en) * | 2020-04-02 | 2021-10-07 | Egaceutical Corporation | Viral treatment regimens |
| CN113521090A (zh) * | 2020-04-21 | 2021-10-22 | 百瑞全球有限公司 | 抗衰老组合物、包含其的药物和保健品、及其应用 |
| CN111599476B (zh) * | 2020-05-15 | 2023-08-11 | 中南大学湘雅医院 | 一种高血压的预测模型及其建立方法以及用于预测高血压的生物标记物 |
| CN111635885B (zh) * | 2020-06-11 | 2023-08-29 | 深圳市旷逸生物科技有限公司 | 一种提高脐带间质干细胞抗氧化能力的培养方法 |
| NL1044089B1 (en) * | 2020-08-12 | 2022-07-15 | Dr Jelena Barjaktarovic Md | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) |
| NL1044087B1 (en) * | 2020-08-12 | 2022-07-08 | Dr Jelena Barjaktarovic Md | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) |
| CN111939154A (zh) * | 2020-08-24 | 2020-11-17 | 周琛 | 抗衰老组合物及其用途和含有它的保健食品与药品 |
| US20220088045A1 (en) * | 2020-09-23 | 2022-03-24 | Mo S. Kharazmi | Treatment compositions |
| CN112137977A (zh) * | 2020-09-28 | 2020-12-29 | 深圳雾件科技有限公司 | 一种烟酰胺单核苷酸缓释肠溶口崩片及其制备方法 |
| CN112089705A (zh) * | 2020-09-28 | 2020-12-18 | 深圳雾件科技有限公司 | 一种烟酰胺单核苷酸微囊及其制备方法 |
| AU2022258448A1 (en) * | 2021-04-13 | 2023-11-09 | Animal Biosciences, Inc. | Formulations of nicotinic acid derivatives and flavonoid polyphenols and uses thereof |
| KR20240020716A (ko) | 2021-05-27 | 2024-02-15 | 메트로 인터내셔널 바이오테크 엘엘씨 | 니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법 |
| WO2022269064A1 (en) * | 2021-06-24 | 2022-12-29 | Vestlandets Innovasjonsselskap As (Vis) | Nad-augmentation therapy for parkinson's disease |
| WO2023037173A1 (en) * | 2021-07-12 | 2023-03-16 | Matthias W Rath | A pharmaceutical micronutrient composition for use to simultaneously improve nervous system function, cognitive ability and response to stressors |
| CN115414375B (zh) * | 2022-11-03 | 2023-03-24 | 卡瑞济(北京)生命科技有限公司 | 烟酰胺单核苷酸延长car-t细胞寿命的用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9920351D0 (en) * | 1999-08-28 | 1999-11-03 | Strachen John S | Sparse constructive node stimulation of cell surface molecular resonance in vivo |
| JP2003171325A (ja) * | 2001-11-30 | 2003-06-20 | Sumitomo Chem Co Ltd | 固体有機化合物の製造方法 |
| KR101010745B1 (ko) * | 2002-04-09 | 2011-01-24 | 오츠카 세이야쿠 가부시키가이샤 | 세포 증식용 조성물 |
| EP1665711B8 (en) * | 2003-09-17 | 2016-12-14 | Google Technology Holdings LLC | System and method for asynchronous wireless services using reverse service schema generation |
| AU2004324323A1 (en) * | 2003-10-31 | 2006-06-15 | Robarts Research Institute | Methods and formulations for protecting cells, and for treating diseases and conditions by optimising the intracellular concentration of NAD |
| CN1299688C (zh) * | 2004-04-29 | 2007-02-14 | 路宁 | 氨基酸溶液及其制备方法 |
| LT1791791T (lt) * | 2004-09-27 | 2019-09-10 | Special Water Patents B.V. | Vandens valymo būdai ir kompozicijos |
| US20060127506A1 (en) * | 2004-12-10 | 2006-06-15 | Hebert Rolland F | Compositions of S-adenosyl-L-methionine |
| KR101312422B1 (ko) * | 2004-12-22 | 2013-09-30 | 시바 홀딩 인코포레이티드 | 항라디칼제 |
| CN101360421B (zh) * | 2005-11-18 | 2014-06-18 | 康乃尔研究基金会有限公司 | 烟酰核苷组合物及其使用方法 |
| US9649513B2 (en) * | 2006-03-24 | 2017-05-16 | Colgate—Palmolive Company | Aerosol dispenser |
| CN101926459A (zh) * | 2009-11-20 | 2010-12-29 | 张小夫 | 一种能提升学习记忆力预防考试焦虑的制剂及制备方法 |
| WO2012114204A2 (en) * | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
| RU2488376C1 (ru) * | 2012-01-26 | 2013-07-27 | Екатерина Александровна Диброва | Способ лечения и оздоровления организма человека |
| US20140004097A1 (en) * | 2012-06-29 | 2014-01-02 | Shire Human Genetic Therapies, Inc. | Method of producing recombinant iduronate-2-sulfatase |
| CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
| JP6545256B2 (ja) * | 2015-03-31 | 2019-07-17 | 新興和製薬株式会社 | レスベラトロールとニコチンアミドモノヌクレオチドを含む食品組成物 |
-
2016
- 2016-10-03 JP JP2018538047A patent/JP2018530614A/ja active Pending
- 2016-10-03 RU RU2018114520A patent/RU2768936C2/ru active
- 2016-10-03 WO PCT/US2016/055173 patent/WO2017062311A1/en active Application Filing
- 2016-10-03 SG SG11201802933YA patent/SG11201802933YA/en unknown
- 2016-10-03 EP EP16854140.7A patent/EP3359259B1/en active Active
- 2016-10-03 KR KR1020187011865A patent/KR20180063179A/ko not_active Application Discontinuation
- 2016-10-03 MX MX2018004358A patent/MX2018004358A/es unknown
- 2016-10-03 IL IL299824A patent/IL299824B2/en unknown
- 2016-10-03 CN CN201680071250.1A patent/CN108290059A/zh active Pending
- 2016-10-03 CA CA3001483A patent/CA3001483A1/en active Pending
- 2016-10-03 AU AU2016335968A patent/AU2016335968B2/en active Active
- 2016-10-03 US US15/766,990 patent/US20190060336A1/en not_active Abandoned
- 2016-10-03 BR BR112018007153A patent/BR112018007153A2/pt not_active Application Discontinuation
- 2016-10-03 CA CA3118834A patent/CA3118834C/en active Active
-
2018
- 2018-04-08 IL IL258541A patent/IL258541B/en unknown
- 2018-04-09 MX MX2022013626A patent/MX2022013626A/es unknown
-
2019
- 2019-01-17 HK HK19100813.4A patent/HK1258406A1/zh unknown
-
2021
- 2021-07-15 US US17/376,621 patent/US20220023323A1/en active Pending
-
2022
- 2022-04-24 IL IL292414A patent/IL292414B2/en unknown
- 2022-05-25 JP JP2022084999A patent/JP2022122921A/ja active Pending
-
2023
- 2023-01-04 AU AU2023200040A patent/AU2023200040A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL292414B2 (en) | 2023-06-01 |
| US20190060336A1 (en) | 2019-02-28 |
| IL258541B (en) | 2022-05-01 |
| IL299824B1 (en) | 2023-10-01 |
| IL299824B2 (en) | 2024-02-01 |
| BR112018007153A2 (pt) | 2018-11-06 |
| AU2023200040A1 (en) | 2023-02-09 |
| EP3359259A1 (en) | 2018-08-15 |
| CA3118834A1 (en) | 2017-04-13 |
| RU2018114520A (ru) | 2019-11-07 |
| IL258541A (en) | 2018-05-31 |
| CA3001483A1 (en) | 2017-04-13 |
| CN108290059A (zh) | 2018-07-17 |
| WO2017062311A1 (en) | 2017-04-13 |
| MX2022013626A (es) | 2022-11-16 |
| RU2018114520A3 (es) | 2020-02-21 |
| JP2018530614A (ja) | 2018-10-18 |
| EP3359259B1 (en) | 2023-11-15 |
| AU2016335968B2 (en) | 2022-10-27 |
| KR20180063179A (ko) | 2018-06-11 |
| AU2016335968A1 (en) | 2018-05-10 |
| EP3359259A4 (en) | 2019-04-24 |
| JP2022122921A (ja) | 2022-08-23 |
| IL292414A (en) | 2022-06-01 |
| HK1258406A1 (zh) | 2019-11-08 |
| IL299824A (en) | 2023-03-01 |
| EP3359259C0 (en) | 2023-11-15 |
| SG11201802933YA (en) | 2018-05-30 |
| CA3118834C (en) | 2024-06-11 |
| RU2768936C2 (ru) | 2022-03-25 |
| US20220023323A1 (en) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018004358A (es) | Restablecimiento de rutas biológicas para defender contra el deterioro por el envejecimiento humano y repararlo. | |
| BR112018071573A2 (pt) | composto, método e composto nrta | |
| CL2022000603A1 (es) | Inhibidores prmt5 cooperativos de mta | |
| CL2018002997A1 (es) | Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción. | |
| MX2018001363A (es) | Derivados del mononucleotido de nicotinamida y sus usos. | |
| BR112017019409A2 (pt) | forma cristalina de ribosídeo de nicotinamida | |
| EA201692422A1 (ru) | Состав, содержащий пролекарство гемцитабина | |
| BR112017019696A2 (pt) | composto e usos de um composto | |
| CR20120120A (es) | Metodos para el tratamiento de un sarcoma utilizando un cambiador epimetabolico (coenzima q10) | |
| CU20180027A7 (es) | DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
| MX2015008888A (es) | Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. | |
| EA033118B1 (ru) | Способы разделения диастереоизомеров фосфата гемцитабина | |
| BR112015004650A2 (pt) | implantes ósseos de compósito | |
| UY36265A (es) | “derivados de pirrolo[2,3-d]pirimidina”. | |
| MX2018015302A (es) | Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos. | |
| BR112019006932A2 (pt) | composições antimicrobianas | |
| PH12018501341A1 (en) | Formulations of phosphoramidate derivatives of nucleoside drugs | |
| CY1117881T1 (el) | Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων | |
| EP4292651A3 (en) | Liponucleotide-based therapy for ards | |
| MX2018011970A (es) | Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-pir an-4-il)amino)-8-((2,4,6-triclorofenilo)amino)-9h-purin-9-il)-1-m etilciclohexano-1-carboxamida y métodos para utilizarlas. | |
| MX2019009610A (es) | Metodos para aumentar en plasma sanguineo la 2'-desoxiuridina (durd) y la inhibicion de la timidilato sintasa. | |
| MX2017009289A (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
| EP3730508A4 (en) | LIVER RELEASE BASED COMPOUND OF GEMCITABIN PRODRUG AND NUCLEOSIDE CYCLIC PHOSPHATE AND APPLICATION THEREOF | |
| GEP20196957B (en) | Crystalline forms of s-acetyl glutathione, their reparations and uses in pharmaceutical and nutraceutical formulations | |
| BR112015029699A2 (pt) | prótese total do joelho, e método para a montagem de uma prótese total do joelho |